CY1108330T1 - Ανθρωπινο κυκλοφορητικο ανασταλτικο για ιο πεπτιδιο (virip) και η χρησιμοποιηση του - Google Patents

Ανθρωπινο κυκλοφορητικο ανασταλτικο για ιο πεπτιδιο (virip) και η χρησιμοποιηση του

Info

Publication number
CY1108330T1
CY1108330T1 CY20081100976T CY081100976T CY1108330T1 CY 1108330 T1 CY1108330 T1 CY 1108330T1 CY 20081100976 T CY20081100976 T CY 20081100976T CY 081100976 T CY081100976 T CY 081100976T CY 1108330 T1 CY1108330 T1 CY 1108330T1
Authority
CY
Cyprus
Prior art keywords
virip
virus
activity
antagonist
inhibitor
Prior art date
Application number
CY20081100976T
Other languages
English (en)
Inventor
Frank Kirchhoff
Jan Münch
Ludger Ständker
Wolf-Georg Forssmann
Knut Adermann
Original Assignee
Ipf Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999153732 external-priority patent/DE19953732A1/de
Priority claimed from DE2000123665 external-priority patent/DE10023665A1/de
Application filed by Ipf Pharmaceuticals Gmbh filed Critical Ipf Pharmaceuticals Gmbh
Publication of CY1108330T1 publication Critical patent/CY1108330T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)

Abstract

Πεπτίδιο με την παρακάτω ακολουθία αμινοξέων: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP), καθώς και τα βιολογικά ενεργά θραύσματα και/ή οι εκδοχές και/ή τα παράγωγα του, ειδικότερα αμιδιωμένα, ακετυλιωμένα, σουλφουρωμένα, τροποποιημένα με πολυαιθυλενογλυκόλη (PEG), φωσφορυλιωμένα και/ή γλυκοζυλιωμένα παράγωγα, καθώς και τα παραγόμενα με πολλαπλή σύνθεση πεπτίδια, το οποία έχουν την βιολογική δραστικότητα του VIRIP, σε αυτά Ζ1, Ζ2 αντιπροσωπεύουν ανεξάρτητα μεταξύ τους έναν αριθμό από 0 έως 10 ρίζες αμινοξέων, και εφόσον Ζ1 ή Ζ2 = σημαίνουν 0 ρίζες αμινοξέων, τότε Ζ1 = Η και/ή Ζ2 = COOH.
CY20081100976T 1999-11-08 2008-09-10 Ανθρωπινο κυκλοφορητικο ανασταλτικο για ιο πεπτιδιο (virip) και η χρησιμοποιηση του CY1108330T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999153732 DE19953732A1 (de) 1999-11-08 1999-11-08 Humanes zirkulierendes Virus inhibierendes Peptid (VIRIP) und seine Verwendung
DE2000123665 DE10023665A1 (de) 2000-05-16 2000-05-16 Humanes zirkulierendes Virus inhibierendes Peptid (VIRIP) und seine Verwendung
EP00987221A EP1228203B1 (de) 1999-11-08 2000-11-08 Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung

Publications (1)

Publication Number Publication Date
CY1108330T1 true CY1108330T1 (el) 2014-02-12

Family

ID=26005679

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100976T CY1108330T1 (el) 1999-11-08 2008-09-10 Ανθρωπινο κυκλοφορητικο ανασταλτικο για ιο πεπτιδιο (virip) και η χρησιμοποιηση του

Country Status (13)

Country Link
US (1) US7037896B1 (el)
EP (2) EP1959013B1 (el)
JP (1) JP4813720B2 (el)
AT (1) ATE398674T1 (el)
AU (1) AU2354801A (el)
CA (1) CA2390652C (el)
CY (1) CY1108330T1 (el)
DE (1) DE50015216D1 (el)
DK (1) DK1228203T3 (el)
ES (1) ES2307549T3 (el)
HK (1) HK1124083A1 (el)
PT (1) PT1228203E (el)
WO (1) WO2001034640A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20100144630A1 (en) * 1999-03-05 2010-06-10 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
CA2509423A1 (en) * 2002-12-19 2004-07-08 Ipf Pharmaceuticals Gmbh Peptides and their use for the treatment of hiv infections
US20070123465A1 (en) * 2004-06-18 2007-05-31 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of hiv infections
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
CN102507824B (zh) * 2011-11-01 2013-10-09 北京三元基因工程有限公司 聚乙二醇修饰蛋白质的修饰位点分析方法
EP3473650A1 (en) * 2017-10-18 2019-04-24 Universitätsklinikum Jena Antibody for the specific detection of caap47/48 fragments
WO2021146715A1 (en) * 2020-01-16 2021-07-22 Case Western Reserve University Neutrophil elastase binding peptides and compositions thereof
WO2022083729A1 (en) * 2020-10-22 2022-04-28 The University Of Hong Kong Compositions of anti-viral peptides and/or compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1303530C (en) 1983-01-21 1992-06-16 Michael Courtney EXPRESSION VECTORS AND THEIR USE FOR THE PREPARATION OF A PROTEIN HAVING HUMAN .alpha. -ANTITRYPSIN ACTIVITY
US5827662A (en) 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
EP0616614A1 (en) * 1991-04-18 1994-09-28 The Uab Research Foundation Compositions and methods for inhibiting elastase
US5175253A (en) 1991-04-24 1992-12-29 Washington University Binding peptides
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
WO2001008708A2 (en) 1999-07-29 2001-02-08 Case Western Reserve University Enhanced delivery via serpin enzyme complex receptor ligands

Also Published As

Publication number Publication date
WO2001034640A2 (de) 2001-05-17
US7037896B1 (en) 2006-05-02
PT1228203E (pt) 2008-09-03
JP2003516729A (ja) 2003-05-20
EP1228203B1 (de) 2008-06-18
DE50015216D1 (de) 2008-07-31
EP1959013A1 (de) 2008-08-20
EP1228203A2 (de) 2002-08-07
CA2390652C (en) 2011-03-29
AU2354801A (en) 2001-06-06
EP1959013B1 (de) 2014-04-23
ES2307549T3 (es) 2008-12-01
HK1124083A1 (en) 2009-07-03
CA2390652A1 (en) 2001-05-17
DK1228203T3 (da) 2008-10-20
JP4813720B2 (ja) 2011-11-09
WO2001034640A3 (de) 2001-11-01
ATE398674T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
CY1108330T1 (el) Ανθρωπινο κυκλοφορητικο ανασταλτικο για ιο πεπτιδιο (virip) και η χρησιμοποιηση του
Bodenmüller et al. Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans
Novogrodsky et al. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors
Deuel et al. Expression of a platelet-derived growth factor-like protein in simian sarcoma virus transformed cells
EP0665754B1 (en) Antimicrobial peptides
EP0862455B1 (en) Interferon-polymer conjugates and process for preparing the same
Silverman et al. Specific binding sites for muramyl peptides on murine macrophages.
HUT75058A (en) Amplification of the vitamin b12 uptake system using polymers
US6251866B1 (en) Conjugates targeted to the interleukin-2 receptor
EP1037657A4 (en) ALPHA INTERFERON-POLYMER CONJUGATES WITH INCREASED BIOLOGICAL EFFECTIVENESS AND METHOD FOR THE PRODUCTION THEREOF
JPH01501939A (ja) 免疫抑制ペプチドおよび使用法
US5627035A (en) Peptides that block human immunodeficiency virus and methods of use thereof
CN1781933B (zh) 胸腺素α1活性片段环肽类似物及其聚乙二醇化衍生物
US8026207B2 (en) Peptides and compositions for inhibiting fungal growth
Rastogi et al. Augmentation of human natural killer cells by splenopentin analogs
EP0635027B1 (en) Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis
CN1962693A (zh) 长效胸腺素α1的聚乙二醇化修饰物
EP0858808B1 (en) Peptides for use in wound treatment
EP0545991B1 (en) Peptides that block human immunodeficiency virus infections and methods of use thereof
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
Birr Synthetic small thymic peptides: an immunoregulatory concept
CA2398395A1 (en) Conjugates targeted to target receptors
Naider et al. Inhibition of oligopeptide transport in S. cerevisiae by a peptide-poly (ethylene glycol) conjugate
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
Aggeli et al. Design of Synthetic Branched Chain Polymeric Polypeptides for Targeting/Delivering Bioactive Molecules